Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Mallinckrodt
Colorcon
AstraZeneca
Merck

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OPTISON

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Optison

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00186953 Determination of a Safe Dose of Optison in Pediatric Patients With Solid Tumors Completed St. Jude Children's Research Hospital Phase 1 2002-06-01 St. Jude Children's Research Hospital is studying ways to make ultrasound images clearer - to be able to see blood vessels, body structures, and tumors better. Ultrasound uses sound waves to create pictures, allowing doctors and other medical professionals to "see" inside the body. Researchers are studying a contrast agent (like a dye) called Optison™. St. Jude Children's Research Hospital researchers want to learn the best and safest dose of this ultrasound "dye."
NCT00286559 Assessing Myocardial Blood Flow and Blood Flow Reserve by Transoesophageal Echocardiography (TEE) Withdrawn University Hospital, Basel, Switzerland Phase 1/Phase 2 2006-08-01 Until today it was not possible to reliably assess the function of a new bypass, i.e., to measure myocardial perfusion. Measuring intramyocardial blood flow directly after revascularisation would greatly improve the assessment of graft function. With transthoracic contrast echocardiography, myocardial perfusion can be reliably assessed, as it has been shown in numerous studies. In the first part of the study the investigators will clarify methodological aspects of contrast echocardiography. In the second part they will analyze the validity of contrast TEE in the operating room.
NCT00580580 Detection of Coronary Stenosis With Intravenous Microbubbles Withdrawn University of Nebraska N/A 2012-02-01 To detect coronary artery disease by both coronary and carotid artery imaging and myocardial perfusion imaging using a new low mechanical index real time system.
NCT00730964 A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice. Completed GE Healthcare Phase 4 2008-05-01 This prospective surveillance trial will gather safety information for Optison when it is used in routine practice.
NCT00878878 Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR). Completed ICON Clinical Research Phase 4 2009-03-01 The design of this study is to conduct a comprehensive safety evaluation of the pulmonary hemodynamic effects of Optison. The study is being conducted in subjects referred for cardiac catheterization for clinical reasons.
NCT00878878 Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR). Completed GE Healthcare Phase 4 2009-03-01 The design of this study is to conduct a comprehensive safety evaluation of the pulmonary hemodynamic effects of Optison. The study is being conducted in subjects referred for cardiac catheterization for clinical reasons.
NCT01394926 Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease Terminated GE Healthcare Phase 2 2011-06-01 The purpose of this study is to find the optimal dose from 3 different dose levels - 0.15 mL, 0.5 mL and 1.5 mL of Optison in assessing the presence of disease of the carotid arteries when comparing pre-contrast to post-contrast ultrasound (U/S) by dose group.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Optison

Condition Name

Condition Name for Optison
Intervention Trials
Coronary Artery Disease 2
Vesico-Ureteral Reflux 1
Carotid Stenosis 1
Kidney Transplantation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Optison
Intervention Trials
Carcinoma 2
Myocardial Ischemia 2
Coronary Disease 2
Coronary Artery Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Optison

Trials by Country

Trials by Country for Optison
Location Trials
United States 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Optison
Location Trials
Pennsylvania 3
New Jersey 2
Nebraska 2
Texas 1
Michigan 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Optison

Clinical Trial Phase

Clinical Trial Phase for Optison
Clinical Trial Phase Trials
Phase 4 4
Phase 2 2
Phase 1/Phase 2 3
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Optison
Clinical Trial Phase Trials
Completed 4
Recruiting 4
Withdrawn 3
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Optison

Sponsor Name

Sponsor Name for Optison
Sponsor Trials
GE Healthcare 6
Chiltern International Inc. 1
Astellas Pharma US, Inc. 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Optison
Sponsor Trials
Other 14
Industry 9
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
AstraZeneca
Moodys
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.